SciELO - Scientific Electronic Library Online

 
vol.110 número8Keriorrea (diarrea cérea), un nuevo signo a tener en cuentaDispepsia, dispepsia funcional y criterios de Roma IV índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.110 no.8 Madrid ago. 2018

https://dx.doi.org/10.17235/reed.2018.5603/2018 

LETTERS

Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease

Blanca Martínez-Andrés1  , Violeta Sastre-Lozano1  , José-Francisco Sánchez-Melgarejo1 

1Sección Aparato Digestivo. Hospital General Universitario Morales Meseguer. Murcia, Spain

Key words: Crohn's disease; Vedolizumab; Sweet syndrome

Dear Editor,

The adverse pharmacological reactions in the management of inflammatory bowel disease (IBD) complicate the proper use of biological therapies. The effectiveness and safety of vedolizumab described in the article by Olmedo-Martín 1 was read in detail.

In this study, a 42-year-old patient with colon Crohn's disease and a primary failure after two anti-TNF in treatment with azathioprine was admitted due to a severe outbreak with severe endoscopic activity. There was no response to corticosteroids and, therefore, an induction regimen with vedolizumab was initiated. After 24 hours, small pustules began to appear on the back, neck, chest and scalp and a post-infusional adverse reaction was suspected, although the digestive symptoms had improved. The lesions progressed to large violaceous plates, presenting leukocytosis with neutrophilia. The case was assessed by the Dermatology Service, confirming Sweet syndrome associated with Crohn's disease (Fig. 1). A skin biopsy was performed that confirmed the diagnosis. A second dose of vedolizumab was administered without any further incidents.

Fig. 1 Skin lesions. 

Discussion

Sweet syndrome or acute febrile neutrophilic dermatosis is an uncommon cutaneous manifestation in IBD 2,3. It is characterized by the appearance of erythematous and painful plaques located predominantly on the arms, upper area of the trunk, neck and face. It is generally associated with a deterioration of the general state, leukocytosis, neutrophilia and fever. In our case, the absence of fever and the appearance of skin lesions after administration of the drug made us initially suspect an adverse reaction to vedolizumab. However, the multidisciplinary management and adequate differential diagnosis of the skin lesions finally allowed treatment with vedolizumab to be maintained and the goal of clinical and endoscopic remission was achieved in our patient.

Bibliografía

1. Olmedo-Martín RV, Amo-Trillo V, González-Grande R, et al. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Rev Esp Enferm Dig 2017;109(9):659-62. DOI: 10.17235/reed.2017.5024/2017 [ Links ]

2. Ortega-Alonso A, López-Navarro N, Gallego E, et al. Crohn's disease and Sweet's syndrome: a debut together. Rev Esp Enferm Dig 2015;107(12):765-6. [ Links ]

3. Catalán-Serra I, Martín-Moraleda L, Navarro-López L, et al. Crohn's disease and Sweet's syndrome: an uncommon association. Rev Esp Enferm Dig 2010;102(5):331-7. DOI: 10.4321/S1130-01082010000500009 [ Links ]

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons